Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $110.34 million
- Book Value:
- Revenue TTM:
- $33.82 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Chimerix Inc had its IPO on 2013-04-11 under the ticker symbol CMRX.
The company operates in the Healthcare sector and Biotechnology industry. Chimerix Inc has a staff strength of 89 employees.
Shares of Chimerix Inc opened at $1.24 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $1.2 - $1.25, and closed at $1.22.
This is a -2.4% slip from the previous day's closing price.
A total volume of 653,020 shares were traded at the close of the day’s session.
In the last one week, shares of Chimerix Inc have slipped by -8.96%.
Chimerix Inc's Key Ratios
Chimerix Inc has a market cap of $110.34 million, indicating a price to book ratio of 0.6267 and a price to sales ratio of 5.2738.
In the last 12-months Chimerix Inc’s revenue was $33.82 million with a gross profit of $-36486000 and an EBITDA of $-58434000. The EBITDA ratio measures Chimerix Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Chimerix Inc’s operating margin was -173.05% while its return on assets stood at -19.26% with a return of equity of 105.91%.
In Q4, Chimerix Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1669.6%.
Chimerix Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $1.77 per share while it has a forward price to earnings multiple of 1.2136 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Chimerix Inc’s profitability.
Chimerix Inc stock is trading at a EV to sales ratio of 3.5749 and a EV to EBITDA ratio of 1.4568. Its price to sales ratio in the trailing 12-months stood at 5.2738.
Chimerix Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $279.34 million
- Total Liabilities
- $20.42 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Chimerix Inc ended 2023 with $279.34 million in total assets and $0 in total liabilities. Its intangible assets were valued at $279.34 million while shareholder equity stood at $256.86 million.
Chimerix Inc ended 2023 with $0 in deferred long-term liabilities, $20.42 million in other current liabilities, 88000.00 in common stock, $-713429000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $25.84 million and cash and short-term investments were $217.33 million. The company’s total short-term debt was $0 while long-term debt stood at $250000.00.
Chimerix Inc’s total current assets stands at $228.14 million while long-term investments were $48.63 million and short-term investments were $191.49 million. Its net receivables were $1.04 million compared to accounts payable of $3.03 million and inventory worth $0.00.
In 2023, Chimerix Inc's operating cash flow was $-228399000.00 while its capital expenditure stood at $71000.
Comparatively, Chimerix Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Chimerix Inc stock is currently trading at $1.22 per share. It touched a 52-week high of $5.39 and a 52-week low of $5.39. Analysts tracking the stock have a 12-month average target price of $7.5.
Its 50-day moving average was $1.64 and 200-day moving average was $1.95 The short ratio stood at 3.82 indicating a short percent outstanding of 0%.
Around 995.6% of the company’s stock are held by insiders while 6464.4% are held by institutions.
Frequently Asked Questions About Chimerix Inc
Similar Industry Stocks (Biotechnology)
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.